NASDAQ:SCTX Scribe Therapeutics Q2 2026 Earnings Results & Report $20.77 +1.65 (+8.63%) As of 10/14/2026 04:00 PM Eastern Scribe Therapeutics beat analyst earnings expectations but missed on revenue in its Q2 2026 results, released September 2, 2026. The company reported EPS of -$3.84 versus the -$6.20 consensus estimate, while revenue of $1.92 million fell short of the $3.10 million estimate by $1.18 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateSeptember 2, 2026TimeAfter Market ClosesConference Call4:00 PM ET Scribe Therapeutics EPS ResultsActual EPS-$3.84Consensus EPS -$6.20Beat/MissBeat by +$2.36One Year Ago EPSN/AScribe Therapeutics Revenue ResultsActual Revenue$1.92 millionExpected Revenue$3.10 millionBeat/MissMissed by -$1.18 millionYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Scribe Therapeutics Q2 2026 Earnings FAQ Did Scribe Therapeutics beat earnings estimates for Q2 2026? Scribe Therapeutics (NASDAQ:SCTX) reported earnings of -$3.84 per share for Q2 2026, beating the consensus estimate of -$6.20. The report was announced on Wednesday, September 2, 2026. What was Scribe Therapeutics' revenue for Q2 2026? Scribe Therapeutics reported revenue of $1.92 million for Q2 2026, against a consensus estimate of $3.10 million. Scribe Therapeutics Earnings HeadlinesScribe Surges On IPO Debut -- But All Eyes Turn To 1H27 DataSeptember 27, 2026 | seekingalpha.comPronóstico para Scribe TherapeuticsSeptember 23, 2026 | mx.investing.comThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.October 15 at 1:00 AM | Investors Alley (Ad)Scribe Therapeutics (SCTX) Stock Price, Quote, News & History | BenzingaSeptember 23, 2026 | benzinga.comScribe Reports Narrower Loss In Q2 Due To Lower ExpensesSeptember 3, 2026 | rttnews.comScribe starts phase 1 trial for cholesterol drug STX-1150September 2, 2026 | msn.comSee More Scribe Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Scribe Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Scribe Therapeutics and other key companies, straight to your email. Email Address About Scribe TherapeuticsScribe Therapeutics (NASDAQ:SCTX) is a biotechnology company focused on developing CRISPR-based gene-editing technologies and therapeutic applications. Its work centers on engineering gene-editing systems designed to improve precision, delivery and performance for potential use in the treatment of human disease. The company’s platform is intended to support the development of therapies that can modify genetic material in targeted cells. Scribe Therapeutics has also pursued research collaborations and partnerships aimed at applying its gene-editing technology across multiple therapeutic areas. Scribe Therapeutics is based in the United States and has operated as a privately held biotechnology company. Publicly available information does not reliably confirm that the company is listed on Nasdaq under the symbol “SCTX”; that ticker information may refer to a different entity.View Scribe Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Citi Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenUnitedHealth Beats on Earnings, But Investors Question Growth PathIREN Limited's AI Pivot Gains Traction—But Can Its Data Centers Deliver?PBF Energy's Stunning Rally Faces a Critical TestA Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Albertsons Is Betting on a Turnaround—But Will It Pay Off? Upcoming Earnings Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
